HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care, has joined a European cardiovascular research consortium to lead a pivotal clinical study. The initiative, called EXIT-CVD, is co-funded by the European Union Innovative Health Initiative and industry partners, and aims to transform cardiovascular care through large-scale research. HeartBeam’s role in leading the HEART-CHECK study highlights the company’s growing influence in cardiac monitoring and its potential to address a critical unmet need in post-acute coronary syndrome care.
The EXIT-CVD consortium, led by University Medical Center Groningen and Royal Philips, brings together 42 organizations across 17 countries. It will conduct 22 clinical studies involving more than 14,000 patients, supported by a total budget of 27.6 million euros. This scale of collaboration signals a strong commitment to advancing cardiovascular research and integrating innovative technologies into real-world care pathways. For HeartBeam, participation provides access to a diverse patient population and a rigorous research environment that could generate robust clinical evidence for its portable ECG system.
HeartBeam will lead the HEART-CHECK study, which will evaluate its portable electrocardiogram (ECG) system for early detection and triage of cardiac events in high-risk patients recently discharged following acute coronary syndrome. The study will assess the system’s clinical performance and integration into real-world care pathways. This is significant because patients discharged after a heart attack remain at high risk for recurrent events, yet continuous monitoring options are limited. HeartBeam’s cable-free, 3D ECG technology could enable at-home assessment, potentially catching complications earlier and reducing hospital readmissions.
The HeartBeam System recently received U.S. Food and Drug Administration Breakthrough Device Designation for at-home heart attack assessment, an application that remains investigational. This designation is reserved for devices that offer more effective treatment or diagnosis of life-threatening conditions, and it could expedite regulatory review. The HEART-CHECK study will complement that effort by generating European clinical data, which may support broader adoption and regulatory submissions in other regions. For investors, this news underscores HeartBeam’s progress toward commercializing its technology and expanding its global footprint.
HeartBeam’s technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This platform is intended for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians could then identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement.
The EXIT-CVD consortium and the HEART-CHECK study represent a major opportunity for HeartBeam to validate its technology in a large, diverse patient population. If successful, the study could position HeartBeam as a key player in the shift toward decentralized cardiac care. For more details on the company’s cleared indications, refer to the Cleared Indications for Use. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. To view the full press release, visit https://ibn.fm/52Qtj.
InvestorWire, a specialized communications platform, distributed this announcement. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers corporate communications solutions and social media distribution to enhance visibility. For full terms of use, see the https://www.InvestorWire.com/Disclaimer.
